Perioperative bleeding in cardiac surgery is related to both surgical trauma of blood vessels and defects in the hemostatic mechanism caused, in part, by cardiopulmonary bypass. Blood transfusion therefore remains a significant risk of cardiac surgery with important health and economic consequences. Blood conservation strategies for cardiac surgery have advanced over the years and the following discussion will focus on the current practices at Toronto General Hospital.
Get full access to this article
View all access options for this article.
References
1.
1. Goodnough LT, Soegiarso W, Birlmeier JD, Welch HG: The economic impact of inappropriate blood transfusion in coronary artery bypass graft surgery. Am J Med94:509-514, 1993.
2.
2. Johnson RG, Thurer RL, Kruskall MS: Comparison of two transfusion strategies after elective operations for myocardial revascularization. J Thorac Cardiovasc Surg104:307-314, 1992.
3.
3. Goodnough T, Johnston MD, Ramsey MD: Guidelines for transfusion support in patients undergoing coronary artery bypass grafting. Ann Thorac Surg50:675-683, 1990.
4.
4. Crosby E, for Expert Working Group: Guidelines for red blood cell and plasma transfusion for adults and children. Can Med Assoc J156(suppl 11):1997.
5.
5. Stover EP, Siegel LC, Parks R: Variability in transfusion practice for coronary artery bypass surgery persists despite national consensus guidelines. Anesthesiology88:327-333, 1998.
6.
6. Belisle S, Hardy JF. Hemorrhage and the use of blood products after adult cardiac operations: Myths and realities. Ann Thorac Surg62:1908-1917, 1996.
7.
7. Scott WJ, Kessler R, Wernly JA: Blood conservation in cardiac surgery. Ann Thorac Surg50:843-851, 1990.
8.
8. Hardy JF, Belisle S, Janvier G: Reduction in requirements for allogeneic blood products: Nonpharmacologic methods. Ann Thorac Surg62:1935-1943, 1996.
9.
9. Janssens M, Hartstein G, David JL: Reduction in requirements for allogeneic blood products: Pharmacologic Methods. Ann Thorac Surg62:1944-1950, 1996.
10.
10. Karski JM, Matthieu M, Cheng D: Etiology of preoperative anemia in patients undergoing scheduled cardiac surgery. Can J Anesth46:979-982, 1999.
11.
11. Dacey LJ, Munoz JJ, Baribeau YR: Reexploration for hemorrhage following coronary artery bypass grafting: Incidence and risk factors. Northern England Cardiovascular Disease Study Group. Arch Surg133:442-447, 1998.
12.
12. Talamonti MS, LoCicero J III, Hoyne WP: Early re-exploration for excessive postoperative bleeding lowers wound complication rates in open heart surgery. Am Surg53:102-104, 1987.
13.
13. Karski JM, Teasedale SJ, Norman P: Prevention of post bypass bleeding with tranexamic acid and e-aminocaproic acid. J Cardiothorac Vasc Anesth7:431-435, 1993.
14.
14. Karski JM, Joiner R, Carroll J: Comparison of the effect of 3 different doses of tranexamic acid on postoperative bleeding in cardiac surgery performed without active systemic cooling. Society of Cardiovascular Anesthesiologists Annual Meeting, Montreal, 1994, p XX-XX.
15.
15. Karski JM, Teasedale SJ, Norman P: Prevention of postcardiopulmonary bypass bleeding with high dose tranexamic acid: Double-blinded, randomized clinical trial. J Thorac Cardiovasc Surg110:835-842, 1995.
16.
16. Holloway DS, Summaria L, Sandesara J: Decreased platelet number and function and increased fibrinolysis contribute to postoperative bleeding in cardiopulmonary bypass patients. Thromb Haemost59:62-67, 1988.
17.
17. Mammen EF, Koets MH, Washington BC: Hemostasis changes during cardiopulmonary bypass surgery. Semin Thromb Hemost11:281-292, 1985.
18.
18. Kestin AS, Valeri R, Khuri SF: The platelet function defect of cardiopulmonary bypass. Blood82:107-117, 1993.
19.
19. Cramer EM, Lu H, Caen J: Differential redistribution of platelet glycoproteins Ib and IIb-IIIa after plasmin stimulation. Blood77:694-699,1991.
20.
20. Lu H, Soria C, Crammer EM: Temperature dependence of plasmin-induced activation or inhibition of human platelets. Blood77:996-1005, 1991.
21.
21. Lu H, Soria C, Soria J: Reversible translocation of glycoprotein Ib in plasmin-treated platelets: Consequences for platelet function. Eur J Clin Invest23:785-793, 1993.
22.
22. Magovern JA, Sakert T, Benckart DH: A model for predicting transfusion after coronary artery bypass grafting. Ann Thorac Surg61:27-32, 1996.
23.
23. Ferraris VA, Gildengorin V: Predictors of excessive blood use after coronary artery bypass grafting. A multivariate analysis. J Thorac Cardiovasc Surg98:492-497, 1989.
24.
24. Ferraris VA, Ferraris SP: Preoperative aspirin ingestion increases operative blood loss after coronary artery bypass grafting (update). Ann Thorac Surg59:1036-1037, 1995.
25.
25. Gammie JS, Zenati M, Kormos R: Abciximab and excessive bleeding in patients undergoing emergency cardiac operations. Ann Thorac Surg465-469, 1997.
26.
26. Despotis GJ, Skubas NJ, Goodnough TG: Optimal management of bleeding and transfusion in patients undergoing cardiac surgery. Sem Thorac Cardiovasc Surg11:84-104, 1999.
27.
27. Helm RE, Rosengart TK, Gomez M: Comprehensive multimodality blood conservation: 100 consecutive CABG operations without transfusion. Ann Thorac Surg65:125-136, 1998.
28.
28. Pinkerton PH: Autologous blood donation in support of cardiac surgery: A preliminary report on a hospital based autologous program. Can J Anesth41:1036-1040, 1994.
29.
29. Ferguson D, Blair A, Henry D: Technologies to minimize blood transfusion in cardiac and orthopedic surgery. Results of a practice variation survey in nine countries. Int J Technology Assessment in Health Care15:717-728, 1999.
30.
30. Etchason J, Petz L, Keller E: Cost effectiveness of preoperative blood donations. N Engl J Med332:719-724, 1995.
31.
31. American Society of Anesthesiologists Task Force on Blood Component Therapy: Practice guidelines for blood component therapy: A report by the American Society of Anesthesiologists Task Force on Blood Component Therapy. Anesthesiology84:732-747, 1996.
32.
32. Gillon J, Thomas MJG, Desmond MJ: Consensus conference on autologous transfusion. Acute normovolemic hemodilution. Transfusion36:640-643, 1996.
33.
33. Trouwborst A, van Bommel J: Monitoring normovolemic hemodilution. Br J Anaesth81(suppl):73-78, 1998.
34.
34. Ovrum E, Holen EA, Tangen G: Consistent non-pharmacological blood conservation in primary and reoperative coronary artery bypass grafting. Eur J Cardiothorac Surg9:30-35, 1995.
35.
35. Schonberger JPAM, Bredee JJ, Tjian D: Intraoperative predonation contributes to blood saving. Ann Thorac Surg56:893-898, 1993.
36.
36. Bryson GL, Laupacis A, Wells GA: Does acute normovolemic hemodilution reduce perioperative allogeneic transfusion? A meta-analysis. Anesth Analg86:9-15, 1998.
37.
37. Parolari A, Antona C, Rona P: The effects of multiple blood conservation techniques on donor blood exposure in adult coronary and valve surgery performed with a membrane oxygenator: A multivariate analysis on 1310 patients. J Card Surg10:227-235, 1995.
38.
38. Helm RE, Klemperer JD, Rosengart TK: Intraoperative autologous blood donation preserves red cell mass but does not decrease postoperative bleeding. Ann Thorac Surg62:1431-1441, 1996.
39.
39. British committee for standards in hematology blood transfusion task force: In Napier JAF, Bruce M, Chapman J: Guidelines for autologous transfusion. II Perioperative hemodilution and cell salvage. Br J Anaesth78:768-771, 1997.
43. Schonberger JPAM, van Oeveren W, Bredee JJ: Systemic blood activation during and after autotransfusion. Ann Thorac Surg57:1256-1262, 1944.
44.
44. Morris JJ, Tan YS: Autotransfusion: Is there a benefit in current practice of aggressive blood conservation?Ann Thorac Surg62:1935-1943, 1996.
45.
45. Dietrich W: Pro: Shed mediastinal blood retransfusion should be used routinely in cardiac surgery. J Cardiothorac Vasc Anesth9:95-99, 1995.
46.
46. Body SC, Birmingham J, Parks R: Safety and efficacy of shed mediastinal blood transfusion after cardiac surgery: A multicentre observational study. Multicentre study of perioperative ischemia research group. J Cardiothorac Vasc Anesth13:410-416, 1999.
47.
47. Nguyen DM, Gilfix BM, Dennis F: Impact of transfusion of mediastinal shed blood on serum levels of cardiac enzymes. Ann Thorac Surg62:109-114, 1996.
48.
48. Peters DC, Noble S: Aprotinin: An update of its pharmacology and therapeutic use in open heart surgery and coronary artery bypass surgery. Drugs57:233-260, 1999.
49.
49. Greilich PE, Okada K, Latham P: Aprotinin but not epsilon-aminocaproic acid decreases interleukin-10 after cardiac surgery with extracorporeal circulation. Circulation104(suppl):I-265-I-269, 2001.
50.
50. Poullis M, Manning R, Laffan M: The antithrombotic effect of aprotinin: Actions mediated via the protease activated receptor-1. J Thorac Cardiovasc Surg120:370-378, 2000.
51.
51. Soslau G, Horrow J, Brodsky I: Effect of tranexamic acid on platelet ADP during extracorporeal circulation. Am J Hemat38:113-119, 1991.
52.
52. Huang H, Ding W, Su Z: Mechanism of the preserving effect of aprotinin on platelet function and its use in cardiac surgery. J Thorac Cardiovasc Surg11-18, 1993.
53.
53. Bidstrup BP, Royston D, Sapsford RN: Reduction in blood loss and blood use after cardiopulmonary bypass with high dose aprotinin (Trasylol). J Thorac Cardiovasc Surg97:364-372, 1989.
54.
54. Baele PL, Ruiz-Gomez J, Londot C: Systemic use of aprotinin in cardiac surgery: Influence on total homologous exposure and hospital cost. Acta Anaesthesiol Belg43:103-112, 1992.
55.
55. Havel M, Teufelsbauer H, Knobl P: Effect of intraoperative aprotinin administration on postoperative bleeding in patients undergoing cardiopulmonary bypass operation. J Thorac Cardiovasc Surg101:968-972, 1991.
56.
56. Vedrinne C, Girard C, Jegaden O: Reduction in blood loss and blood use after cardiopulmonary bypass with highdose aprotinin versus autologous fresh whole blood transfusion. J Cardiothorac Vasc Anesth6:319-323, 1992.
57.
57. Harder MP, Eijsman L, Roozendaal KJ: Aprotinin reduces intraoperative and postoperative blood loss in membrane oxygenator cardiopulmonary bypass. Ann Thorac Surg51:936-941, 1991.
58.
58. Lemmer JH, Stanford W, Bonney SL: Aprotinin for coronary bypass operations: Efficacy, safety, and influence on early saphenous vein graft patency. J Thorac Cardiovasc Surg107:543-553, 1994.
59.
59. Swart MJ, Gordon PC, Hayse-Gregson PB: High-dose aprotinin in cardiac surgery: A prospective, randomized study. Anaesth Intensive Care22:529-533, 1994.
60.
60. Rich JB: The efficacy and safety of aprotinin use in cardiac surgery. Ann Thorac Surg66:S6-S11, 1998.
61.
61. Royston D, Bidstrup BP, Taylor KM: Effect of aprotinin on need for blood transfusion after repeat open heart surgery. Lancet2:1289-1291, 1987.
62.
62. Dietrich D, Barankay A, Hanel C: High dose aprotinin in cardiac surgery: Three years' experience in 1,784 patients. J Cardiothorac Vasc Anesth6:324-327, 1992.
63.
63. Royston D: High-dose aprotinin therapy: A review of the first five years' experience. [Review] J Cardiothorac Vasc Anesth6:76-100, 1992.
64.
64. Bidstrup BP, Harrison J, Royston D: Aprotinin therapy in cardiac operations: A report on the use in 41 centres in the United Kingdom. Ann Thorac Surg55:971-976, 1993.
65.
65. Levi M, Cromheecke ME, de Jonge E: Pharmacological strategies to decrease excessive blood loss in cardiac surgery: A meta-analysis of clinically relevant end points. Lancet354:1940-1947, 1999.
66.
66. Cosgrove DM, Heric B, Lytle BW: Aprotinin therapy for reoperative myocardial revascularization: A placebo-controlled study. Ann Thorac Surg54:1031-1038, 1992.
67.
67. Liu B, Belboul A, Radberg G: Effect of reduced aprotinin dosage on blood loss and use of blood products in patients undergoing cardiopulmonary bypass. Scand J Thorac Cardiovasc Surg27:149-155, 1993.
68.
68. Hardy JF, Desroches J, Belisle S: Low dose aprotinin infusion is not clinically useful to reduce bleeding and transfusion of homologous blood products in high-risk cardiac surgical patients. Can J Anesth40:625-631, 1993.
69.
69. Covino E, Pepino P, Iorio D: Low dose aprotinin as blood saver in open heart surgery. Eur J Cardiothorac Surg5:414-418, 1991.
70.
70. Gschossmann J, Pracki P, Struck E: Efficacy of aprotinin in different doses and autologous blood transfusions in cardiac surgery. Cardiovasc Surg2:716-719, 1994.
71.
71. Hardy JF, Belisle S, Couturier A: Randomized, placebocontrolled, double-blind study of an ultra-low-dose aprotinin regimen in reoperative and/or complex cardiac operations. J Card Surg12:15-22, 1997.
72.
72. Nuttall GA, Fass DN, Oyen LJ: A study of a weight-adjusted aprotinin dosing schedule during cardiac surgery. Anesth Analg94:283-289, 2002.
73.
73. Levy JH, Bailey JM, Salmenpera M: Pharmacokinetics of aprotinin in preoperative cardiac surgical patients. Anesthesiology80:1013-1018, 1994.
74.
74. Tatar H, Cicek S, Demirkilic U: Topical use of aprotinin in open heart operations. Ann Thorac Surg55:659-661, 1993.
75.
75. O'Regan DJ, Giannopoulos N, Mediratta N: Topical aprotinin in cardiac operations. Ann Thorac Surg58:778-781, 1994.
76.
76. Cicek S, Theodoro DA: Topical aprotinin in cardiac operations: A note of caution. Ann Thorac Surg61:103-104, 1996.
77.
77. Hayashida N, Isomura T, Sato T: Effects of minimal-dose aprotinin on coronary artery bypass grafting. J Thorac Cardiovasc Surg114:261-269, 1997.
79. Dewachter P, Mouton C, Masson C: Anaphylactic reaction to aprotinin during cardiac surgery. Anaesthesia48:1110-1111, 1993.
80.
80. Regoli D, Barabe J: Pharmacology of bradykinin and related kinins. Pharmacol Rev32:1-46, 1980.
81.
81. Proud D, Kaplan AP: Kinin formation: Mechanisms and role in inflammatory disorders. Annu Rev Immunol6:49-83, 1988.
82.
82. Schweizer A, Hohn L, Morel DR: Aprotinin does not impair renal hemodynamics and function after cardiac surgery. Br J Anaesth84:16-22, 2000.
83.
83. Maineri P, Covaia G, Realini M: Postoperative bleeding after coronary revascularization. Comparison between tranexamic acid and epsilon-aminocaproic acid. Minerva Cardioangiol48:155-160, 2000.
84.
84. Fremes SP, Wong BI, Lee E: Meta-analysis of prophylactic drug treatment in the prevention of postoperative bleeding. Ann Thorac Surg58:1580-1588, 1994.
85.
85. Jansen AJ, Andreica S, Claeys M: Tranexamic acid and blood conservation strategy after total knee arthroplasty. Br J Anaesth83:596-601, 1999.
86.
86. Miyashita T, Kamibayashi T, Ohnishi Y: Preservation of collagen-induced whole blood platelet aggregation by tranexamic acid in primary cardiac valve surgery. Perfusion15:507-513, 2000.
87.
87. Horrow JC, Van Riper DF, Strong MD: Haemostatic effects of tranexamic acid and desmopressin during cardiac surgery. Circulation85:2063-2070, 1991.
90. DelRossi AJ, Cernaianu AC, Botros S: Prophylactic treatment of postperfusion bleeding using EACA. Chest96:27-30, 1989.
91.
91. Hardy JF, Belisle S: Natural and synthetic antifibrinolytics in adult cardiac surgery: Efficacy, effectiveness and efficiency. [Review] Can J Anesth41:1104-1112, 1994.
92.
92. Munoz JJ, Birkmeyer NJO, Birkmeyer JD: Is epsilonaminocaproic acid as effective as aprotinin in reducing bleeding with cardiac surgery? A meta-analysis. Circulation99:81-89, 1999.
93.
93. Isetta C, Samat C, Lugrin D: Tranexamic acid is as effective as aprotinin in reducing blood loss and blood requirements after CPB for cardiac surgery in routine patients. Anesth AnalgS1-S581-S206, 1980.
94.
94. Havel M, Grabenvoger F, Schneider J: Aprotinin does not decrease early graft patency after coronary artery bypass grafting despite reducing postoperative bleeding and use of donated blood. J Thorac Cardiovasc Surg107:807-810, 1994.
96. Alderman EL, Levy JH, Rich JB: Analyses of coronary graft patency after aprotinin use: Results from the International Multicenter Aprotinin Graft Patency Experience (IMAGE) trial. J Thorac Cardiovasc Surg116:716-730, 1998.
97.
97. Sheridan DP, Card RT, Pinilla JC: Use of desmopressin acetate to reduce blood transfusion requirements in patients with acetylsalicylic-acid-induced platelet dysfunction. Can J Surg37:33-36, 1994.
98.
98. Laupacis A: Drugs to minimize perioperative blood loss in cardiac surgery: Meta-analysis using perioperative blood transfusion as the outcome. The International Study of Perioperative Transfusion Investigators. Anesth Analg85:1258-1267, 1997.
99.
99. Cattaneo M, Harris A, Stromberg U: The effect of Desmopressin on reducing blood loss in cardiac surgery-A metaanalysis of double-blind, placebo controlled trials. Thromb Hemost74:1064-1070, 1995.
100.
100. Wong BI, McLean RF, Fremes SE: Aprotinin and tranexamic acid for high transfusion risk cardiac surgery. Ann Thorac Surg69:808-816, 2000.
101.
101. Casati V, Guzzon D, Oppizzi M: Tranexamic acid compared with high dose aprotinin in primary elective heart operations: Effects on perioperative bleeding and allogeneic transfusions. J Thorac Cardiovasc Surg120:520-527, 2000.
102.
102. Kiyama H, Ohshima N, Imazeki T: Autologous blood donation with recombinant human erythropoietin in anemic patients. Ann Thorac Surg68:1652-1656, 1999.
103.
103. Coyle D, Lee KM, Fergusson DA: Cost effectiveness of epoetin-alpha to augment preoperative autologous blood donation in elective cardiac surgery. Pharmacoeconomics18:161-171, 2000.
104.
104. Sowade D: Avoidance of allogeneic blood transfusions by treatment with epoetin beta (recombinant human erythropoietin) in patients undergoing open heart surgery. Blood89:411-411, 1997.
105.
105. Spahn DR, Leone BJ, Reves JG: Cardiovascular and coronary physiology of acute isovolemic hemodilution: A review of non-oxygen carrying and oxygen carrying solutions. Anesth Analg78:1000-1021, 1994.
106.
106. Dietz NM, Joyner MJ, Warner MA: Blood substitutes: Fluids drugs or miracle solutions? [Review]. Anesth Analg82:390-405, 1996.
107.
107. Cheng DCH: Safety and efficacy of o-raffinose cross-linked human hemoglobin (Hemolinktm) in cardiac surgery. Can J Anesth48:S41-S48, 2001.
108.
108. Hebert PC, Wells G, Martin C: Variation in red cell transfusion practice in the intensive care unit: A multicentre cohort study. Crit Care3:57-63, 1999.
109.
109. Hebert PC, Szick S: Transfusion in the intensive care unit: Strategies under scrutiny. Curr Opin Anesthesiol13:119-123, 2000.
110.
110. Goodnough LT: Transfusion medicine. N Engl J Med340:525-533, 1999.
111.
111. Scott WJ, Rode R, Castlemain B: Efficacy, complications, and cost of a comprehensive blood conservation program for cardiac operations. J Thorac Cardiovasc Surg103:1001-1006; Discussion 1006-1007, 1992.
